Laurence Albiges, MD, PhD

home / authors / laurence-albiges-md-phd

Articles

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 21st 2023

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 21st 2023

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Imaging and Staging Considerations in Renal Cell Carcinoma

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 14th 2023

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Ulka Vaishampayan, MD;Alan Tan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

Ulka Vaishampayan, MD;Laurence Albiges, MD, PhD;Neeraj Agarwal, MD;Matthew T. Campbell, MD, MS;Benjamin Maughan, MD, PharmD;Alan Tan, MD

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Laurence Albigès, MD, PhD, medical oncologist, head, Genitourinary Unit, Department of Medical Oncology, Gustave Roussy Institute, France,

Dr. Albigès on the CaboPoint Trial in Advanced RCC

Laurence Albiges, MD, PhD

February 18th 2023

Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.

<1 2